Avita Medical

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Avita Medical
Public company
Traded as ASXAVH
Industry Regenerative medicine
Founded 1993 (1993)
Founder Fiona Wood
Area served
Products ReCell, ReNovaCell & ReGenerCell
Website avitamedical.com

Avita Medical is a clinical and commercial company developing and marketing a range of respiratory and regenerative products. The first regenerative medicine product brought to the market by Avita Medical was ReCell spray-on skin for the treatment of burns.[1] The two latest products are ReNovaCell, for Aesthetics and Plastic applications including skin trauma, and ReGenerCell for the treatment of chronic wounds. The Avita Medical regenerative product range is currently marketed in EMEA countries and Australia.[2]:9–10

Company History[edit]

Originally named "Clinical Cell Culture" and listed on the ASX under the symbol "C3", the company restructured under the name "Avita Medical" in June 2008. In 2015, the company conducted a strategic divestment of its respiratory business, including the Breath-a-Tech and Funhaler products, to support focus on its regenerative products.[3]

ReCell, Spray-on Skin[edit]

ReCell is a stand-alone, rapid, autologous cell harvesting, processing and delivery technology that enables clinicians to treat wounds and skin defects using very small samples of the patient’s own cells, accelerating the healing process, eliminating tissue rejection, minimizing scar formation and reintroducing normal pigmentation, vascularization and innervation in the treated wound area. The procedure is performed entirely on site at bedside, utilizes a patented and proprietary ‘spray-on’ application technique, takes approximately 25 min to complete and does not require laboratory facilities, off-site culture of tissues or specialized staff. ReCell is approved in EMEA countries, China, and Australia and is in Pivotal/PIII trials in the US for burns as a first indication and a Pilot/PII US study underway for scars.

US Government grant[edit]

In 2009 the United States Armed Forces Institute of Regenerative Medicine provided Avita with a US$1.45 million grant to hasten the approval of the ReCell kit with the U.S. Food and Drug Administration.[4]

Clinical Programs[edit]

In addition to the US studies for ReCell in burns and scars, ReCell is being studied in a number of small scale post-marketing studies in Europe for venous leg ulcers, Vitiligo, acne scars, scar remodeling, facial rejuvenation (wrinkle revision), treatment of donor graft sites, and hard to heal burn wounds in the elderly.


  1. ^ Bland, Eric (November 23, 2009). "Spray-on skin speeds up healing burns". ABC Science. Australian Broadcasting Company. Retrieved December 26, 2015. 
  2. ^ 2015 Concise Annual Report (PDF). Avita Medical. 2015. 
  3. ^ House, Douglas W. (December 24, 2015). "Avita Medical sells respiratory business to MDI for $2.64M". Seeking Alpha. Retrieved December 28, 2015. 
  4. ^ Greenblat, Eli (May 27, 2009). "Avita boosted by US affirmation". The Age.